Masterclass in Systemic Cancer Therapy (MSCT) 2021 Virtual

Advertisement

This masterclass will be offered as a hybrid (in-person or virtual on September 4-5 and 11-12) experience due to COVID-19 pandemic spread.

The theme: "Cancer Therapeutics: Back to Basics, Forward to the Future."

The Department of Clinical Oncology, University of Malaya Medical Centre in conjunction with the Malaysian Oncological Society is proud to be organising its 5th MSCT.

Chemotherapy and Hormonal Therapy (pharmacological aspect of cytotoxics, antimetabolites, topoisomerase inhibitors, platinum agents, antimicrotubules, alkylating agents, response assessment of systemic cancer therapy, acute and late toxicity of systemic treatment, antiemetics, analgesics for cancer pain, endocrine therapy in male/female cancers, tailoring treatment in special situations, mechanism of drug resistance, chemotherapy and pregnancy, fertility issues and fertility sparing options, management of systemic therapy in the COVID-19 era) - September 4-5

Targeted Therapy (personalized medicine in cancer therapeutics, biomarkers and cancer genomic profiling, EGFR-targeted therapy, ALK/ROS-1 inhibitor therapy, multikinase inhibitors I, BRAF/MEK inhibitors, HER-2 targeted therapy, CDK4/6, PIK3CAi, AKT and mTOR inhibitors, somatostatin targeted therapy, PARP inhibitors, immune checkpoint inhibitors, VEGF targeted therapy and multikinase inhibitors II, biosimilars development and challenges, immune-mediated toxicities, rarer mutations/targets and intervention, CAR T cell therapy, high dose chemotherapy) - September 11-12

Date

September 4-12, 2021

Location

Virtual Conference

Email

msctummc2021@gmail.com

Website

www.msctummc2021.com/


The Department of Clinical Oncology, University of Malaya Medical Centre in conjunction with the Malaysian Oncological Society is proud to be organising its 5th MSCT.

Chemotherapy and Hormonal Therapy (pharmacological aspect of cytotoxics, antimetabolites, topoisomerase inhibitors, platinum agents, antimicrotubules, alkylating agents, response assessment of systemic cancer therapy, acute and late toxicity of systemic treatment, antiemetics, analgesics for cancer pain, endocrine therapy in male/female cancers, tailoring treatment in special situations, mechanism of drug resistance, chemotherapy and pregnancy, fertility issues and fertility sparing options, management of systemic therapy in the COVID-19 era) - September 4-5

Targeted Therapy (personalized medicine in cancer therapeutics, biomarkers and cancer genomic profiling, EGFR-targeted therapy, ALK/ROS-1 inhibitor therapy, multikinase inhibitors I, BRAF/MEK inhibitors, HER-2 targeted therapy, CDK4/6, PIK3CAi, AKT and mTOR inhibitors, somatostatin targeted therapy, PARP inhibitors, immune checkpoint inhibitors, VEGF targeted therapy and multikinase inhibitors II, biosimilars development and challenges, immune-mediated toxicities, rarer mutations/targets and intervention, CAR T cell therapy, high dose chemotherapy) - September 11-12" />

Advertisement